Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Anti-CD45 conditioning looks safe, feasible in relapsed AML

Key clinical point: A novel anti-CD45 targeted conditioning regimen appears safe and feasible in older patients with relapsed or refractory acute myeloid leukemia undergoing transplant.

Major finding: Treatment with iodine-131 apamistamab has so for resulted in successful engraftment for all patients who have received it and gone on to transplant.

Study details: Early results from SIERRA, a randomized, phase 3 trial, including data on 38 patients enrolled to date.

Disclosures: The study is supported by Actinium Pharmaceuticals. Dr. Giralt reported disclosures related to Actinium and several other companies.


Giralt SA et al. TCT 2019, Abstract LBA3.